Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PINCH - PD-L1 Imaging for Durvalumab Response in HNSCC
NCT03829007Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2019
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Radboud University Medical Center. Started Apr 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03829007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829007.